Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma
  • +25
  • Dietrich Stovesandt,
  • Friedrich Christian Franke,
  • Adrian Damek,
  • Jonas Steglich,
  • Lars Kurch,
  • Dirk Hasenclever,
  • Thomas Georgi,
  • Walter Wohlgemuth,
  • Christine Mauz-Koerholz,
  • Dieter Körholz,
  • Regine Kluge,
  • Judith Landman-Parker,
  • William Hamish Wallace,
  • Alexander Fosså,
  • Dirk Vordermark,
  • Jonas Karlen,
  • Ana Fernández-Teijeiro,
  • Michaela Cepelova,
  • Tomasz Klekawka,
  • Andishe Attarbaschi,
  • Francesco Ceppi,
  • Andrea Hraskova,
  • Anne Uyttebroeck,
  • Auke Beishuizen,
  • Karin Dieckmann,
  • Thierry Leblanc,
  • Martin Moellers,
  • Boris Buerke
Dietrich Stovesandt
Universitatsklinikum Halle

Corresponding Author:[email protected]

Author Profile
Friedrich Christian Franke
Universitatsklinikum Halle
Author Profile
Adrian Damek
Universitatsklinikum Halle
Author Profile
Jonas Steglich
Universitatsklinikum Halle
Author Profile
Lars Kurch
Universitat Leipzig Medizinische Fakultat
Author Profile
Dirk Hasenclever
Universitat Leipzig Medizinische Fakultat
Author Profile
Thomas Georgi
Universitat Leipzig Medizinische Fakultat
Author Profile
Walter Wohlgemuth
Universitatsklinikum Halle
Author Profile
Christine Mauz-Koerholz
Justus Liebig Universitat Giessen Fachbereich Medizin
Author Profile
Dieter Körholz
Justus Liebig Universitat Giessen Fachbereich Medizin
Author Profile
Regine Kluge
Universitat Leipzig Medizinische Fakultat
Author Profile
Judith Landman-Parker
Sorbonne Universite
Author Profile
William Hamish Wallace
The University of Edinburgh
Author Profile
Alexander Fosså
Oslo Universitetssykehus
Author Profile
Dirk Vordermark
Universitatsklinikum Halle
Author Profile
Jonas Karlen
Karolinska Universitetssjukhuset
Author Profile
Ana Fernández-Teijeiro
Hospital Universitario Virgen Macarena
Author Profile
Michaela Cepelova
Department of Pediatric Hematology and Oncology University Hospital Motol and Second Medical Faculty of Charles University Prague Czech Republic
Author Profile
Tomasz Klekawka
Pediatric Oncology and Hematology Department University Children's Hospital of Krakow Krakow Poland
Author Profile
Andishe Attarbaschi
Medizinische Universitat Wien
Author Profile
Francesco Ceppi
Universite de Lausanne
Author Profile
Andrea Hraskova
Department of Pediatric Hematology and Oncology National Institute of Paediatric Diseases Bratislava Slovakia
Author Profile
Anne Uyttebroeck
Department of Pediatric Hematology and Oncology University Hospitals Leuven Leuven Belgium
Author Profile
Auke Beishuizen
Erasmus MC–Sophia Children’s Hospital Rotterdam The Netherlands
Author Profile
Karin Dieckmann
Department of Radiation Oncology University Hospital Vienna Vienna Austria
Author Profile
Thierry Leblanc
Service d’Hématologie Pédiatrique Hôpital Robert-Debré Paris France
Author Profile
Martin Moellers
Department Department of Pediatric Radiology University Bielefeld Campus Bielefeld-Bethel Bielefeld Germany
Author Profile
Boris Buerke
Universitatsklinikum Munster
Author Profile

Abstract

Background Rebound thymic hyperplasia (RTH) is a common phenomenon caused by stress factors such as chemo- (CTX) or radiotherapy with an incidence of up to 40%. Misinterpretation of RTH and thymic lymphoma relapse (LR) may lead to unnecessary diagnostic procedures including invasive biopsies or treatment intensification. The aim of this study was to identify parameters that differentiate between RTH and thymic LR in the anterior mediastinum. Methods After completion of CTX, we analyzed CTs and MRIs of 291 patients with classical Hodgkin lymphoma (CHL) and adequate imaging available from the European Network for Pediatric Hodgkin lymphoma C1-trial. In all patients with biopsy proven LR an additional FDG-PET-CT was assessed. Structure and morphologic configuration in addition to calcifications and presence of multiple masses in the thymic region and signs of extrathymic LR were evaluated. Results After CTX, a significant volume increase of a new or growing mass in the thymic space occurred in 133 of 291 patients. Without biopsy only 100 patients could be identified as RTH or LR. No single finding related to thymic regrowth allowed differentiation between RTH and LR. However, the vast majority of cases with thymic LR presented with additional increasing tumor masses (34/35). All RTH patients (65/65) presented with isolated thymic growth. Conclusion Isolated thymic LR is very uncommon. CHL relapse should be suspected when increasing tumor masses are present in distant sites outside of the thymic area. Conversely, if regrowth of lymphoma in other sites can be excluded, an isolated thymic mass after CTX likely represents RTH.
12 Aug 2022Submitted to Pediatric Blood & Cancer
12 Aug 2022Submission Checks Completed
12 Aug 2022Assigned to Editor
13 Oct 2022Reviewer(s) Assigned
09 Nov 2022Review(s) Completed, Editorial Evaluation Pending
09 Nov 2022Editorial Decision: Revise Major
27 Jan 2023Submission Checks Completed
27 Jan 2023Assigned to Editor
27 Jan 20231st Revision Received
27 Mar 2023Review(s) Completed, Editorial Evaluation Pending
27 Mar 2023Reviewer(s) Assigned
14 Apr 2023Editorial Decision: Revise Minor
23 Apr 2023Submission Checks Completed
23 Apr 2023Assigned to Editor
23 Apr 20232nd Revision Received
28 Apr 2023Review(s) Completed, Editorial Evaluation Pending
28 Apr 2023Editorial Decision: Accept